• linkedin
  • Increase Font
  • Sharebar

    FDA okays unique injectable for type 2 diabetics

    FDA approved a new once-weekly, single-dose autoinjector device to improve glycemic control in adults with type 2 diabetes.

    Related: FDA approves 2 injectable diabetes drugs

    The agency okayed Bydureon BCise injectable suspension (AstraZeneca), a new formulation of Bydureon, which will be available in the first quarter of 2018.

    The price of Bydureon BCise “will remain at parity with the current list price for Bydureon Pen,” AstraZeneca said in a statement provided to FormularyWatch. “When making any pricing decision, we aim to price responsibly and in line with current treatment costs where treatment options exist; this determination starts and ends with the patient.”

    Related: New diabetes drug enters competitive market

    Unlike other glucagon-like peptide-1 (GLP-1) receptor agonists, Bydureon BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the active ingredient, exenatide, to help patients reach and maintain steady state, according to the statement.

    “The new formulation in the innovative Bydureon BCise device is proven to reduce blood sugar levels, with the added benefit of weight loss,” the statement said.

    Across 2 clinical trials, average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds (1.4 kilograms) were achieved when used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of 2 of these oral anti-diabetic drugs at 28 weeks.

    Read more: New diabetes drug up against leading brands

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available